
TAK Valuation
Takeda Pharmaceutical Co Ltd
- Overview
- Forecast
- Valuation
- Earnings
TAK Relative Valuation
TAK's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TAK is overvalued; if below, it's undervalued.
Historical Valuation
Takeda Pharmaceutical Co Ltd (TAK) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.49 is considered Undervalued compared with the five-year average of 27.81. The fair price of Takeda Pharmaceutical Co Ltd (TAK) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 14.48 USD , Takeda Pharmaceutical Co Ltd is Undervalued By Fair.
Relative Value
Fair Zone
+Inf-+Inf
Current Price:14.48
Fair
Undervalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
0.91
P/B
Median3y
0.93
Median5y
1.01
12.53
FCF Yield
Median3y
11.78
Median5y
13.00
Competitors Valuation Multiple
The average P/S ratio for TAK's competitors is 5.31, providing a benchmark for relative valuation. Takeda Pharmaceutical Co Ltd Corp (TAK) exhibits a P/S ratio of 1.49, which is -71.85% above the industry average. Given its robust revenue growth of 0.24%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
People Also Watch

CCI
Crown Castle Inc
111.480
USD
-2.13%

NET
Cloudflare Inc
198.420
USD
+3.57%

GEHC
GE Healthcare Technologies Inc
77.610
USD
+1.09%

VRSK
Verisk Analytics Inc
297.960
USD
+0.63%

CTSH
Cognizant Technology Solutions Corp
76.670
USD
-0.08%

CPNG
Coupang Inc
30.250
USD
+0.36%

KVUE
Kenvue Inc
22.840
USD
+1.51%

IT
Gartner Inc
356.640
USD
+0.14%

ODFL
Old Dominion Freight Line Inc
167.090
USD
-0.42%

XEL
Xcel Energy Inc
72.660
USD
-0.16%
FAQ

Is Takeda Pharmaceutical Co Ltd (TAK) currently overvalued or undervalued?
Takeda Pharmaceutical Co Ltd (TAK) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.49 is considered Undervalued compared with the five-year average of 27.81. The fair price of Takeda Pharmaceutical Co Ltd (TAK) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 14.48 USD , Takeda Pharmaceutical Co Ltd is Undervalued By Fair .

What is Takeda Pharmaceutical Co Ltd (TAK) fair value?

How does TAK's valuation metrics compare to the industry average?

What is the current P/B ratio for Takeda Pharmaceutical Co Ltd (TAK) as of Jul 27 2025?

What is the current FCF Yield for Takeda Pharmaceutical Co Ltd (TAK) as of Jul 27 2025?

What is the current Forward P/E ratio for Takeda Pharmaceutical Co Ltd (TAK) as of Jul 27 2025?
